Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202

Published: Thursday, December 06, 2012
Last Updated: Thursday, December 06, 2012
Bookmark and Share
New patent covers functional properties of anti-CD38 antibodies.

MorphoSys AG has announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the Company's cancer compound MOR202.

The new patent (US 8,263,746) covers functional properties of anti-CD38 antibodies and provides additional patent protection for MorphoSys's HuCAL antibody MOR202.

The newly issued patent adds to the US patent granted earlier this year covering the antibody's protein sequence as well as pharmaceutical compositions comprising the same.

Together, the two patent families provide strong intellectual property protection for the MOR202 program.

The new patent has a scheduled expiry date in 2025, not including any potential patent office or regulatory extensions.

Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG, commented: "Antibodies targeting CD38 are gathering increased interest from the pharmaceutical industry as a new potential treatment option in multiple myeloma and other forms of leukemia. As with our other proprietary programs, our goal is to build a rich scientific, medical and commercial package around MOR202 in order to lay the groundwork for future partnering. This new patent widens the scope of our patent position around the MOR202 program by covering the functional aspects of anti-CD38 antibodies in addition to protecting the individual antibody sequence."

MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic target for the treatment of multiple myeloma and certain forms of leukemia.

The fully human HuCAL-antibody is currently being tested in a phase 1/2a trial in patients with relapsed/refractory multiple myeloma.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MorphoSys Publishes Update on MOR202 in Multiple Myeloma
First data from final 16 mg/kg dose escalation cohort and combination with immunomodulatory drugs show encouraging activity.
Thursday, September 24, 2015
MorphoSys Provides an Update on its Proprietary Development Portfolio
Lead cancer program MOR208 to be examined in numerous combination studies in hematological cancers.
Thursday, September 10, 2015
MorphoSys and Immatics Enter Strategic Alliance in Immuno-oncology
Collaboration aims to develop novel antibody-based therapies targeting tumor-associated peptides derived from intracellular proteins.
Tuesday, August 25, 2015
MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study
Phase 1 study to evaluate the novel oncology immunotherapeutic MOR209/ES414 for prostate cancer.
Wednesday, March 11, 2015
MorphoSys Announces Additional Clinical Trial of MOR208
Phase 2 study in CLL will evaluate MOR208 in combination with lenalidomide.
Wednesday, December 11, 2013
MorphoSys Strengthens European Patent Position on Anti-CD19 Cancer Program MOR208
New patent has a scheduled expiry date in 2027.
Tuesday, December 03, 2013
MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208
New patent covers the antibody's protein sequence.
Tuesday, October 22, 2013
MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208
Extended treatment resulted in higher overall response rate.
Tuesday, October 08, 2013
MorphoSys Signs Three-Year Protein Engineering Alliance on Slonomics Technology
License agreement covers the delivery of multiple Slonomics®-based DNA libraries.
Monday, February 27, 2012
MorphoSys Signs Long-term Alliance with Pfizer on Sloning Technology Platform
Sloning's Slonomics® platform will be installed at Pfizer's subsidiary Rinat Neuroscience Corp. for fabrication of gene and protein libraries.
Sunday, December 12, 2010
MorphoSys Licenses HuCAL PLATINUM® Antibody Library to Shionogi in Research Partnership
Shionogi expands its current research license to cover the use of MorphoSys's HuCAL PLATINUM technology in drug discovery.
Friday, January 29, 2010
MorphoSys Nominates First Pre-Development Program in Antibody Collaboration
MorphoSys has exercised its first option to participate in the development of a therapeutic antibody program within its collaboration with Novartis.
Wednesday, September 24, 2008
MorphoSys Opens new Facilities in Oxford, UK
UK Minister of Science Malcolm Wicks inaugurates MorphoSys’ 2,200 square meters UK headquarters in North Oxford.
Monday, January 22, 2007
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Genes Help Track Odd Migrations of Zika Mosquitoes
Study shows that mosquitoes carrying Zika virus or Dengue fever a genetically distinct around the world.
Editing Gene Mutations in Anemia
Researchers successfully use a new gene editing strategy to correct mutations that cause a form of anemia.
Lab-on-a-Chip to Help Detect Cancer
In this podcast, we speak to Gustavo Stolovitsky to learn about his career and the work he is doing at IBM Research.
Rare Immunodeficiency Yields Unexpected Insights
Scientists uncover previously unknown gene mutation revealing the role of a key molecule involved in immune cell development.
Driving Mosquito Evolution to Fight Malaria
Researchers propose insect repellent in conjunction with insecticides to extend current insecticide lifetime.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
ALS Study Reveals Role of RNA-Binding Proteins
The findings are a significant step forward in validating RNA-based therapy as a treatment for ALS.
Observing Direct Inheritance of Gene-Silencing RNA
Research has allowed for the observation of double-stranded RNA molecule being passed from parent to offspring in roundworms.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos